Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting 1377 enrolled National Cancer Institute (NCI)

Non-randomizedParallel-groupOpen-labelScreening

Summary

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Timeline

Start: 2017-07-31
Primary completion: 2025-03-31
Completion: 2027-01-06

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ensartinib	Small molecule	—	Oral
Subject	Erdafitinib	Small molecule	—	Oral
Subject	Ivosidenib	Small molecule	—	Oral
Subject	Larotrectinib	Small molecule	—	Oral
Subject	Olaparib	Small molecule	—	Oral
Subject	Palbociclib	Small molecule	—	Oral
Subject	Samotolisib	Small molecule	—	Oral
Subject	Selpercatinib	Small molecule	—	Oral
Subject	Selumetinib	Small molecule	—	Oral
Subject	Tazemetostat	Small molecule	—	Oral
Subject	Ulixertinib	Small molecule	—	Oral
Subject	Vemurafenib	Small molecule	—	Oral
Subject	tipifarnib	Small molecule	—	Oral

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Summary

Timeline

Publications

Drugs

Indications